Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
Kathryn M. Zunich
Henry Clifford Lane
Howard A. Masur
AIDS research and human retroviruses
View on PubMed
Abstract & Figures
Sorry, we couldn't extract an abstract for this paper.
Adverse reaction to drug
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Slides referencing similar topics
» Burden of influenza illness in HIV-infected population » Immunogenicity of influenza vaccines in HIV-infected adults » Efficacy of trivalent influenza vaccine (TIV) in HIV-infected adults » Immunogenicity of influenza vaccines in HIV-infected children » Efficacy of TIV in HIV-infected children » Studies on TIV in HIV-infected and HIV-uninfected pregnant women for protection of mothers and young infants
Nov 11, 2017
Prevention of Tuberculosis in HIV-Infected Individuals
Richard E. Chaisson + 4 • Aug 16, 2017
Cancer and end stage organ disease in HIV-infected individuals
Christine Durand • Oct 27, 2017